Latest research

Researchers have investigated how the risk of developing long term disability has changed over the last three decades for people whose MS begins in childhood.

The number of people being diagnosed with multiple sclerosis around the world is increasing. In this article we take a look at recent research which investigates who might be more succeptible to multiple sclerosis and why that might be. 

The MS Trust is very disappointed that NICE is unable to recommend ozanimod as an NHS treatment for relapsing remitting MS in England and Wales.

Researchers have identified three new MRI-based subtypes are better able to predict MS activity, disability progression and treatment response than the standard relapsing and progressive subtypes.

The MS Trust is delighted that ofatumumab (Kesimpta) has been approved by NICE for people with active relapsing remitting multiple sclerosis.

Under-the-skin (subcutaneous) injection of Tysabri (natalizumab) has been approved for UK and Ireland.

The MHRA has granted marketing authorisation for ofatumumab (Kesimpta) for active relapsing remitting MS.

Researchers have investigated how long it takes for disease modifying drugs to be fully effective at reducing relapses and slowing progression.

This study compared the effectiveness of amantadine, modafinil and methylphenidate with placebo in people with MS-related fatigue.

The MS Trust is delighted that ozanimod (Zeposia) has been approved in Scotland for people with active relapsing remitting multiple sclerosis.

There is more to exercise than physical fitness. This review looks at recent research which shows how exercise has a direct beneficial effect on brain repair processes.

Following our last interview on the subject of the Covid-19 vaccine and people with MS, we received a lot of follow up questions. To answer some of these, we spoke once again to Professor Alasdair Coles, Consultant Neurologist at Addenbrooke’s hospital.